BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31715538)

  • 1. Immunotherapy and other systemic therapies for cutaneous SCC.
    Guminski A; Stein B
    Oral Oncol; 2019 Dec; 99():104459. PubMed ID: 31715538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The occurrence of non-melanoma malignant skin lesions and non-cutaneous squamous-cell carcinoma among metastatic melanoma patients: an observational cohort study in Denmark.
    Li H; Pedersen L; Nørgaard M; Ulrichsen SP; Thygesen SK; Nelson JJ
    BMC Cancer; 2016 May; 16():295. PubMed ID: 27141983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma.
    Zhao CY; Hwang SJE; Anforth R; Carlos G; Chou S; Carlino M; Fernández-Peñas P
    J Immunother; 2018 Sep; 41(7):343-349. PubMed ID: 29939876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic therapy for advanced cutaneous squamous cell carcinoma.
    Fitzgerald K; Tsai KK
    Semin Cutan Med Surg; 2019 Mar; 38(1):E67-E74. PubMed ID: 31051028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma.
    Ahmed SR; Petersen E; Patel R; Migden MR
    Expert Rev Clin Pharmacol; 2019 Oct; 12(10):947-951. PubMed ID: 31524530
    [No Abstract]   [Full Text] [Related]  

  • 6. Desensitization Protocol for Cemiplimab-Related Infusion Reaction in Cutaneous Squamous Cell Carcinoma: A Case Report and Literature Review.
    Banini M; Salvestrini V; Vultaggio A; Perlato M; Mecheri V; Cerbai C; Scotti V; Matucci A; Mangoni M; Livi L; Bonomo P
    Curr Oncol; 2023 Jul; 30(7):6699-6707. PubMed ID: 37504351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic Immunotherapy for Advanced Cutaneous Squamous Cell Carcinoma.
    Ogata D; Tsuchida T
    Curr Treat Options Oncol; 2019 Mar; 20(4):30. PubMed ID: 30874952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durable Response of Metastatic Squamous Cell Carcinoma of the Skin to Ipilimumab Immunotherapy.
    Day F; Kumar M; Fenton L; Gedye C
    J Immunother; 2017 Jan; 40(1):36-38. PubMed ID: 27684455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical treatment of advanced cutaneous squamous-cell carcinoma.
    Gellrich FF; Hüning S; Beissert S; Eigentler T; Stockfleth E; Gutzmer R; Meier F
    J Eur Acad Dermatol Venereol; 2019 Dec; 33 Suppl 8():38-43. PubMed ID: 31833610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies--a case series.
    Eder J; Simonitsch-Klupp I; Trautinger F
    Eur J Dermatol; 2013; 23(5):658-62. PubMed ID: 24135559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.
    Hernández-Guerrero T; Doger B; Moreno V
    Drugs Today (Barc); 2019 Aug; 55(8):485-494. PubMed ID: 31461085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy in head and neck cancer: aiming at EXTREME precision.
    Szturz P; Vermorken JB
    BMC Med; 2017 Jun; 15(1):110. PubMed ID: 28571578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment approaches in immunosuppressed patients with advanced cutaneous squamous cell carcinoma.
    Willenbrink TJ; Jambusaria-Pahlajani A; Arron S; Seckin D; Harwood CA; Proby CM
    J Eur Acad Dermatol Venereol; 2019 Dec; 33 Suppl 8():57-60. PubMed ID: 31833603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromosome 3q arm gain linked to immunotherapy response in advanced cutaneous squamous cell carcinoma.
    Kacew AJ; Harris EJ; Lorch JH; Haddad RI; Chau NG; Rabinowits G; LeBoeuf NR; Schmults CD; Thakuria M; MacConaill LE; Hanna GJ
    Eur J Cancer; 2019 May; 113():1-9. PubMed ID: 30954880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intralesional and systemic immunotherapy for metastatic melanoma.
    Luu C; Khushalani NI; Zager JS
    Expert Opin Biol Ther; 2016 Dec; 16(12):1491-1499. PubMed ID: 27602429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged Response to Pembrolizumab in Spindle Cell Squamous Cell Carcinoma Metastatic to the Central Nervous System.
    Liu Y; Fitzgerald B; Perry E; Pathak A; Chao HH
    J Investig Med High Impact Case Rep; 2019; 7():2324709619850216. PubMed ID: 31132886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for Merkel Cell Carcinoma.
    Nagase K; Narisawa Y
    Curr Treat Options Oncol; 2018 Sep; 19(11):57. PubMed ID: 30238195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors.
    Anforth R; Blumetti TC; Clements A; Kefford R; Long GV; Fernandez-Peñas P
    Br J Dermatol; 2013 Dec; 169(6):1310-3. PubMed ID: 23870055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Possible immunotherapies of skin cancers].
    Lengyel LZS; Gyulai GYR
    Magy Onkol; 2019 Sep; 63(3):239-245. PubMed ID: 31538441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.